Collateral susceptibility-guided alternation of ceftolozane/tazobactam with imipenem prevents resistance development in XDR Pseudomonas aeruginosa biofilms

Collateral susceptibility-guided alternation of ceftolozane/tazobactam with imipenem prevents resistance development in XDR Pseudomonas aeruginosa biofilms

Objectives: New combinations of β-lactams and β-lactamase inhibitors, such as ceftolozane/tazobactam could be useful to combat biofilm-driven chronic infections by extensively resistant (XDR) Pseudomonas aeruginosa but resistance development by mutations in the Ω-loop of AmpC has been described. How...

Full description

Saved in:

Bibliographic Details
Main Authors:	María Fernández-Billón, Elena Jordana-Lluch, Aina E. Llambías-Cabot, María A. Gomis-Font, Pablo Fraile-Ribot, Rosa I. Torrandell, Pamela J. Colman-Vega, Óscar Murillo, María D. Macià, Antonio Oliver
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Series:	Biofilm
Subjects:	Pseudomonas aeruginosa XDR Biofilms Antagonistic resistance mechanisms to antibiotics
Online Access:	http://www.sciencedirect.com/science/article/pii/S259020752400056X
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Use of Ceftolozane-Tazobactam in Patient with Severe Medium Chronic Purulent Otitis by XDR Pseudomonas aeruginosa
by: L. M. Saraca, et al.
Published: (2019-01-01)

Bacteremia in a human caused by an XDR strain of Pseudomonas fulva
by: Fakhur Uddin, et al.
Published: (2018-07-01)

XDR TB in South Africa - What lies ahead?
by: V. Thaver, et al.
Published: (2007-12-01)

Impacts of MDR/XDR-TB on the global tuberculosis epidemic: Challenges and opportunities
by: Kai Ling Chin, et al.
Published: (2024-01-01)

Identification of Acinetobacter baumannii and Determination of MDR and XDR Strains
by: Noor Hussein Ahmad, et al.
Published: (2020-07-01)

Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy
by: Luigi R. Codecasa, et al.
Published: (2017-01-01)

Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis
by: Mario Pezzi, et al.
Published: (2019-01-01)

The growing concern of MDR/XDR bacteria in patients undergoing dialysis: a cross-sectional study
by: Noor S. Kadhem, et al.
Published: (2025-06-01)

The effect of the current chemotherapy of MDR/XDR tuberculosis on QT interval changes in ECG
by: E. M. Zhukova, et al.
Published: (2019-12-01)

Treatment of Polymicrobial Osteomyelitis with Ceftolozane-Tazobactam: Case Report and Sensitivity Testing of Isolates
by: Jeffrey C. Jolliff, et al.
Published: (2016-01-01)

Mechanisms of ceftolozane/tazobactam resistance in Pseudomonas aeruginosa isolates from South Korea
by: Yu Mi Wi, et al.
Published: (2024-12-01)

Experience of using a combination mucoactive drug during chemotherapy in patients with MDR/XDR tuberculosis
by: E. P. Myshkova, et al.
Published: (2020-08-01)

Genotypic and Phenotypic Methods in the Detection of MDR-TB and Evolution to XDR-TB
by: Natalia Zaporojan, et al.
Published: (2025-07-01)

Xpert MTB/XDR Assay for Detection of Resistance to Isoniazid, Fluoroquinolone, Aminoglycoside, and Ethionamide Among Patients with Pulmonary Tuberculosis in Bangladesh
by: S. M. Mazidur Rahman, et al.
Published: (2025-03-01)

Delamanid in the Treatment of MDR/pre-XDR TB in Arkhangelsk Region in 2019–2021
by: E. S. Khimova, et al.
Published: (2023-07-01)

Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings
by: A. V. Kukurika, et al.
Published: (2022-12-01)

In vitro activity of ceftolozane/tazobactam against ESBL-producing enterobacterales in China: SMART 2016–2019
by: Wei Yu, et al.
Published: (2025-05-01)

Activity of ceftolozane/tazobactam against commonly encountered antimicrobial resistant Gram-negative bacteria in Lebanon
by: George F Araj, et al.
Published: (2020-06-01)

Active phytoconstituents to tackle the resistance mechanism of MDR and XDR bacteria: A critical review
by: Subhasmita Mallik, et al.
Published: (2025-08-01)

Investigation of Therapeutic Efficacy of Intravesical Tigecycline Administration in Rats with Cystitis Induced by Extensively Drug-Resistant (XDR), Tigecycline-Sensitive <i>Acinetobacter baumannii</i> Strain
by: Cihan Yüksel, et al.
Published: (2025-06-01)

Ceftazidime-Induced Overexpression of MexJK-OprM Confers Resistance to Ceftolozane/Tazobactam in an Isolate of Pseudomonas aeruginosa
by: Sato T, et al.
Published: (2025-08-01)

Molecular and genomic insights into multidrug-resistant (MDR) and extensively drug-resistant (XDR) Pseudomonas aeruginosa causing burn wound infections in Bangladesh
by: Spencer Mark Mondol, et al.
Published: (2025-07-01)

Assessment of in vitro antimicrobial activities of ceftolozane/tazobactam and ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa clinical isolates
by: Dalia Salem, et al.
Published: (2025-04-01)

The Dissemination of Multidrug Resistance (MDR) and Extensively Drug Resistant (XDR) among Uropathogenic E. coli (UPEC) Isolates from Urinary Tract Infection Patients in Babylon Province, Iraq
by: Al-Hasnawy et al.
Published: (2019-12-01)

Ceftolozane/tazobactam use and emergence of resistance: a 4-year analysis of antimicrobial susceptibility in Pseudomonas aeruginosa isolates in a tertiary hospital
by: Alessandra Imeneo, et al.
Published: (2025-04-01)

Unveiling results and insights from multinational, multicenter Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam Real-world Analysis (SPECTRA)
by: Alex Soriano, et al.
Published: (2025-03-01)

Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort studyResearch in context
by: Yousra Kherabi, et al.
Published: (2025-09-01)

Testing Susceptibility of <i>M. tuberculosis</i> to Second Line Anti-Tuberculosis Drugs Using the XDR Test in Clinical Trials and International Professional Testing Cycles
by: L. V. Domotenko, et al.
Published: (2021-09-01)

Facile Synthesis of <i>N</i>-(4-Bromo-3-methylphenyl)pyrazine-2-carboxamide Derivatives, Their Antibacterial Activities against Clinically Isolated XDR <i>S. Typhi</i>, Alkaline Phosphatase Inhibitor Activities, and Docking Studies
by: Abdul Hannan Khan, et al.
Published: (2024-09-01)

Resistance and heteroresistance to colistin among multidrug-resistant and extensively drug-resistant Gram-negative organisms isolated from patients admitted to Zagazig University Hospitals
by: Salah Al-Sayed Ibrahim Ali, et al.
Published: (2025-03-01)

CEFTOLOZANE/TAZOBACTAM AND CEFTAZIDIME/AVIBACTAM: TWO NOVEL в-LACTAM / β-LACTAMASE INHIBITOR COMBINATION AGENTS FOR THE TREATMENT OF RESISTANT GRAM-NEGATIVE BACTERIAL INFECTIONS
by: J. L. Liscio, et al.
Published: (2020-05-01)

The New Definition and Epidemiology of Extensive Drug Resistant Tuberculosis in 2020
by: S. A. Sterlikov, et al.
Published: (2023-04-01)

A Survival Analysis of Successful and Poor Treatment Outcome Among Patients with Drug-Resistant Tuberculosis and the Associated Factors: A Retrospective Cohort Study
by: Putri Bungsu Machmud, et al.
Published: (2021-07-01)

Real World Experience of Bedaquiline-Based Anti-Tubercular Regime in Multi-Drug Resistant Tuberculosis.
by: Vikas Marwah, et al.
Published: (2025-01-01)

Coexistence of seven different carbapenemase producers in a single hospital admission screening confirmed by whole-genome sequencing
by: Frieder Fuchs, et al.
Published: (2024-12-01)

Accurate analysis method of network element performance and service data characteristics
by: Xuanyu GUO
Published: (2019-10-01)

An unequivocal superbug: PDR Klebsiella pneumoniae with an arsenal of resistance and virulence factor genes
by: Ahmad Sleiman, et al.
Published: (2021-03-01)

TB financing in East Europe promotes unnecessary hospital admissions: the case of Armenia
by: Laura Gillini, et al.
Published: (2013-03-01)

Physicochemical Exploration and Computational Analysis of Bone After Subchronic Exposure to Kalach 360 SL in Female <i>Wistar</i> Rats
by: Latifa Hamdaoui, et al.
Published: (2025-05-01)

Perspectives of targeted chemotherapy with delamanid in the treatment regimens of those with multiple/extensive drug resistant tuberculosis. A success, chance or uncertainty?
by: Aleksey G. Naumov, et al.
Published: (2018-11-01)